Top

Journal of Mammary Gland Biology and Neoplasia

Published in:

01-12-2008

Crosstalk Between IGF1R and Estrogen Receptor Signaling in Breast Cancer

Authors: Dedra H. Fagan, Douglas Yee

Published in: Journal of Mammary Gland Biology and Neoplasia | Issue 4/2008

Abstract

After the discovery that depriving certain breast tumors of estrogen promoted tumor regression, therapeutic strategies aimed at depriving tumors of this hormone were developed. The tumorigenic properties of estrogen are regulated through the estrogen receptor-α (ER), making understanding the mechanisms that activate this receptor highly relevant. In addition to estrogen activating the ER, other growth factor pathways, such as the insulin-like growth factors (IGFs), can activate the ER. This review will examine the interaction between these two pathways. Estrogen can activate the growth stimulatory properties of the IGF pathway via ER’s genomic and non-genomic functions. Further, blockade of ER function can inhibit IGF-mediated mitogenesis and blocking IGF action can inhibit estrogen stimulation of breast cancer cells. Collectively, these observations suggest that the two growth regulatory pathways are tightly linked and a more thorough understanding of the mechanism of this crosstalk could lead to improved therapeutic strategies in breast cancer.

Beatson G. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896;2:162–7. doi:10.1016/S0140-6736(01)72384-7.CrossRef

Allen E, Doisy EA. An ovarian hormone: Preliminary reports on its localization, extraction and partial purification and action in test animals. JAMA 1923;81:810–21.

Jensen EV, Jacobson HI. Basic guides to the mechanism of estrogen action. Recent Prog Horm Res 1962;18:387–414.

Green S, Walter P, Kumar V, Krust A, Bornert JM, Argos P, et al. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 1986;320:134–9. doi:10.1038/320134a0.PubMedCrossRef

O’Malley BW, Conneely OM. Orphan receptors: in search of a unifying hypothesis for activation. Mol Endocrinol. 1992;6:1359–61. doi:10.1210/me.6.9.1359.PubMedCrossRef

Parker MG. Steroid and related receptors. Curr Opin Cell Biol. 1993;5:499–504. doi:10.1016/0955-0674(93)90016-J.PubMedCrossRef

Lees JA, Fawell SE, Parker MG. Identification of two transactivation domains in the mouse oestrogen receptor. Nucleic Acids Res. 1989;17:5477–88. doi:10.1093/nar/17.14.5477.PubMedCrossRef

Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA. 1996;93:5925–30. doi:10.1073/pnas.93.12.5925.PubMedCrossRef

Osborne CK, Schiff R, Fuqua SA, Shou J. Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res. 2001;7:4338s–42s. discussion 411s–2s.PubMed

10.

Beato M. Gene regulation by steroid hormones. Cell 1989;56:335–44. doi:10.1016/0092-8674(89)90237-7.PubMedCrossRef

11.

Klein-Hitpass L, Ryffel GU, Heitlinger E, Cato AC. A 13 bp palindrome is a functional estrogen responsive element and interacts specifically with estrogen receptor. Nucleic Acids Res. 1988;16:647–63. doi:10.1093/nar/16.2.647.PubMedCrossRef

12.

Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, et al. Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol. 2000;74:311–7. doi:10.1016/S0960-0760(00)00108-4.PubMedCrossRef

13.

Safe S. Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions. Vitam Horm. 2001;62:231–52. doi:10.1016/S0083-6729(01)62006-5.PubMedCrossRef

14.

Song RX, Barnes CJ, Zhang Z, Bao Y, Kumar R, Santen RJ. The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. Proc Natl Acad Sci USA. 2004;101:2076–81. doi:10.1073/pnas.0308334100.PubMedCrossRef

15.

MacGregor JI, Jordan VC. Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev. 1998;50:151–96.PubMed

16.

Paige LA, Christensen DJ, Gron H, Norris JD, Gottlin EB, Padilla KM, et al. Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta. Proc Natl Acad Sci USA. 1999;96:3999–4004. doi:10.1073/pnas.96.7.3999.PubMedCrossRef

17.

Knowlden JM, Hutcheson IR, Barrow D, Gee JM, Nicholson RI. Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. Endocrinology 2005;146:4609–18. doi:10.1210/en.2005-0247.PubMedCrossRef

18.

Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 2008;68:826–33. doi:10.1158/0008-5472.CAN-07-2707.PubMedCrossRef

19.

Early Breast Cancer Trialists’ Collaborative Group. Ovarian ablation for early breast cancer. Cochrane Database Syst Rev. 2000;CD000485.

20.

Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991;51:3867–73.PubMed

21.

Pietras RJ. Biologic basis of sequential and combination therapies for hormone-responsive breast cancer. Oncologist 2006;11:704–17. doi:10.1634/theoncologist.11-7-704.PubMedCrossRef

22.

Favoni RE, de Cupis A, Ravera F, Cantoni C, Pirani P, Ardizzoni A, et al. Expression and function of the insulin-like growth factor I system in human non-small-cell lung cancer and normal lung cell lines. Int J Cancer. 1994;56:858–66. doi:10.1002/ijc.2910560618.PubMedCrossRef

23.

Hassan AB, Macaulay VM. The insulin-like growth factor system as a therapeutic target in colorectal cancer. Ann Oncol. 2002;13:349–56. doi:10.1093/annonc/mdf096.PubMedCrossRef

24.

Lee AV, Hilsenbeck SG, Yee D. IGF system components as prognostic markers in breast cancer. Breast Cancer Res Treat. 1998;47:295–302. doi:10.1023/A:1005915420341.PubMedCrossRef

25.

LeRoith D, Roberts CT Jr. Insulin-like growth factors and their receptors in normal physiology and pathological states. J Pediatr Endocrinol Metab 1993;6:251–5.

26.

Ciampolillo A, De Tullio C, Giorgino F. The IGF-I/IGF-I receptor pathway: implications in the pathophysiology of thyroid cancer. Curr Med Chem 2005;12:2881–91. doi:10.2174/092986705774454715.PubMedCrossRef

27.

Tanno S, Mitsuuchi Y, Altomare DA, Xiao GH, Testa JR. AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. Cancer Res. 2001;61:589–93.PubMed

28.

Alexia C, Fallot G, Lasfer M, Schweizer-Groyer G, Groyer A. An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. Biochem Pharmacol. 2004;68:1003–15. doi:10.1016/j.bcp.2004.05.029.PubMedCrossRef

29.

Bonnette SG, Hadsell DL. Targeted disruption of the IGF-I receptor gene decreases cellular proliferation in mammary terminal end buds. Endocrinology 2001;142:4937–45. doi:10.1210/en.142.11.4937.PubMedCrossRef

30.

Kasuya J, Paz IB, Maddux BA, Goldfine ID, Hefta SA, Fujita-Yamaguchi Y. Characterization of human placental insulin-like growth factor-I/insulin hybrid receptors by protein microsequencing and purification. Biochemistry 1993;32:13531–6. doi:10.1021/bi00212a019.PubMedCrossRef

31.

Pandini G, Vigneri R, Costantino A, Frasca F, Ippolito A, Fujita-Yamaguchi Y, et al. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clin Cancer Res. 1999;5:1935–44.PubMed

32.

Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, et al. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol. 1999;19:3278–88.PubMed

33.

Denley A, Carroll JM, Brierley GV, Cosgrove L, Wallace J, Forbes B, et al. Differential activation of insulin receptor substrates 1 and 2 by insulin-like growth factor-activated insulin receptors. Mol Cell Biol. 2007;27:3569–77. doi:10.1128/MCB.01447-06.PubMedCrossRef

34.

Power RF, Mani SK, Codina J, Conneely OM, O’Malley BW. Dopaminergic and ligand-independent activation of steroid hormone receptors. Science 1991;254:1636–9. doi:10.1126/science.1749936.PubMedCrossRef

35.

Ignar-Trowbridge DM, Pimentel M, Parker MG, McLachlan JA, Korach KS. Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol. Endocrinology 1996;137:1735–44. doi:10.1210/en.137.5.1735.PubMedCrossRef

36.

Ignar-Trowbridge DM, Teng CT, Ross KA, Parker MG, Korach KS, McLachlan JA. Peptide growth factors elicit estrogen receptor-dependent transcriptional activation of an estrogen-responsive element. Mol Endocrinol. 1993;7:992–8. doi:10.1210/me.7.8.992.PubMedCrossRef

37.

Ignar-Trowbridge DM, Nelson KG, Bidwell MC, Curtis SW, Washburn TF, McLachlan JA, et al. Coupling of dual signaling pathways: epidermal growth factor action involves the estrogen receptor. Proc Natl Acad Sci USA. 1992;89:4658–62. doi:10.1073/pnas.89.10.4658.PubMedCrossRef

38.

Katzenellenbogen BS, Norman MJ. Multihormonal regulation of the progesterone receptor in MCF-7 human breast cancer cells: interrelationships among insulin/insulin-like growth factor-I, serum, and estrogen. Endocrinology 1990;126:891–8.PubMed

39.

Katzenellenbogen BS. Estrogen receptors: bioactivities and interactions with cell signaling pathways. Biol Reprod. 1996;54:287–93. doi:10.1095/biolreprod54.2.287.PubMedCrossRef

40.

Lee AV, Weng CN, Jackson JG, Yee D. Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. J Endocrinol. 1997;152:39–47. doi:10.1677/joe.0.1520039.PubMedCrossRef

41.

Panno ML, Salerno M, Pezzi V, Sisci D, Maggiolini M, Mauro L, et al. Effect of oestradiol and insulin on the proliferative pattern and on oestrogen and progesterone receptor contents in MCF-7 cells. J Cancer Res Clin Oncol. 1996;122:745–9. doi:10.1007/BF01209122.PubMedCrossRef

42.

El-Tanani MK, Green CD. Two separate mechanisms for ligand-independent activation of the estrogen receptor. Mol Endocrinol. 1997;11:928–37. doi:10.1210/me.11.7.928.PubMedCrossRef

43.

Bunone G, Briand PA, Miksicek RJ, Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 1996;15:2174–83.PubMed

44.

Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995;270:1491–4. doi:10.1126/science.270.5241.1491.PubMedCrossRef

45.

Tremblay GB, Tremblay A, Copeland NG, Gilbert DJ, Jenkins NA, Labrie F, et al. Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta. Mol Endocrinol. 1997;11:353–65. doi:10.1210/me.11.3.353.PubMedCrossRef

46.

Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 2000;407:538–41. doi:10.1038/35035131.PubMedCrossRef

47.

Ruan W, Catanese V, Wieczorek R, Feldman M, Kleinberg DL. Estradiol enhances the stimulatory effect of insulin-like growth factor-I (IGF-I) on mammary development and growth hormone-induced IGF-I messenger ribonucleic acid. Endocrinology 1995;136:1296–302. doi:10.1210/en.136.3.1296.PubMedCrossRef

48.

Richards RG, DiAugustine RP, Petrusz P, Clark GC, Sebastian J. Estradiol stimulates tyrosine phosphorylation of the insulin-like growth factor-1 receptor and insulin receptor substrate-1 in the uterus. Proc Natl Acad Sci USA. 1996;93:12002–7. doi:10.1073/pnas.93.21.12002.PubMedCrossRef

49.

Stewart AJ, Johnson MD, May FE, Westley BR. Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J Biol Chem. 1990;265:21172–8.PubMed

50.

Kleinman D, Karas M, Roberts CT Jr, LeRoith D, Phillip M, Segev Y, et al. Modulation of insulin-like growth factor I (IGF-I) receptors and membrane-associated IGF-binding proteins in endometrial cancer cells by estradiol. Endocrinology 1995;136:2531–7. doi:10.1210/en.136.6.2531.PubMedCrossRef

51.

Figueroa JA, Sharma J, Jackson JG, McDermott MJ, Hilsenbeck SG, Yee D. Recombinant insulin-like growth factor binding protein-1 inhibits IGF-I, serum, and estrogen-dependent growth of MCF-7 human breast cancer cells. J Cell Physiol. 1993;157:229–36. doi:10.1002/jcp.1041570204.PubMedCrossRef

52.

Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev. 2007;28:20–47. doi:10.1210/er.2006-0001.PubMedCrossRef

53.

Freiss G, Rochefort H, Vignon F. Mechanisms of 4-hydroxytamoxifen anti-growth factor activity in breast cancer cells: alterations of growth factor receptor binding sites and tyrosine kinase activity. Biochem Biophys Res Commun. 1990;173:919–26. doi:10.1016/S0006-291X(05)80873-3.PubMedCrossRef

54.

Wakeling AE, Newboult E, Peters SW. Effects of antioestrogens on the proliferation of MCF-7 human breast cancer cells. J Mol Endocrinol. 1989;2:225–34.PubMed

55.

Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG, Coronado-Heinsohn E, Osborne CK, et al. Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol. 1999;13:787–96. doi:10.1210/me.13.5.787.PubMedCrossRef

56.

Lee AV, Darbre P, King RJ. Processing of insulin-like growth factor-II (IGF-II) by human breast cancer cells. Mol Cell Endocrinol. 1994;99:211–20. doi:10.1016/0303-7207(94)90010-8.PubMedCrossRef

57.

Osborne CK, Coronado EB, Kitten LJ, Arteaga CI, Fuqua SA, Ramasharma K, et al. Insulin-like growth factor-II (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor. Mol Endocrinol. 1989;3:1701–9.PubMed

58.

Huynh H, Yang X, Pollak M. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J Biol Chem 1996;271:1016–21. doi:10.1074/jbc.271.2.1016.PubMedCrossRef

59.

Nickerson T, Huynh H, Pollak M. Insulin-like growth factor binding protein-3 induces apoptosis in MCF7 breast cancer cells. Biochem Biophys Res Commun. 1997;237:690–3. doi:10.1006/bbrc.1997.7089.PubMedCrossRef

60.

Mathieu M, Vignon F, Capony F, Rochefort H. Estradiol down-regulates the mannose-6-phosphate/insulin-like growth factor-II receptor gene and induces cathepsin-D in breast cancer cells: a receptor saturation mechanism to increase the secretion of lysosomal proenzymes. Mol Endocrinol. 1991;5:815–22.PubMed

61.

Figueroa JA, Jackson JG, McGuire WL, Krywicki RF, Yee D. Expression of insulin-like growth factor binding proteins in human breast cancer correlates with estrogen receptor status. J Cell Biochem. 1993;52:196–205. doi:10.1002/jcb.240520211.PubMedCrossRef

62.

Stewart AJ, Westley BR, May FE. Modulation of the proliferative response of breast cancer cells to growth factors by oestrogen. Br J Cancer. 1992;66:640–8.PubMed

63.

Salerno M, Sisci D, Mauro L, Guvakova MA, Ando S, Surmacz E. Insulin receptor substrate 1 is a target for the pure antiestrogen ICI 182,780 in breast cancer cells. Int J Cancer. 1999;81:299–304. doi:10.1002/(SICI)1097-0215(19990412)81:2<299::AID-IJC21>3.0.CO;2-8.PubMedCrossRef

64.

Dubik D, Shiu RP. Mechanism of estrogen activation of c-myc oncogene expression. Oncogene 1992;7:1587–94.PubMed

65.

Morishita S, Niwa K, Ichigo S, Hori M, Murase T, Fujimoto J, et al. Overexpressions of c-fos/jun mRNA and their oncoproteins (Fos/Jun) in the mouse uterus treated with three natural estrogens. Cancer Lett. 1995;97:225–31. doi:10.1016/0304-3835(95)03979-7.PubMedCrossRef

66.

Musgrove EA, Sutherland RL. Cell cycle control by steroid hormones. Semin Cancer Biol. 1994;5:381–9.PubMed

67.

Razandi M, Pedram A, Greene GL, Levin ER. Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells. Mol Endocrinol. 1999;13:307–19. doi:10.1210/me.13.2.307.PubMedCrossRef

68.

Kahlert S, Nuedling S, van Eickels M, Vetter H, Meyer R, Grohe C. Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. J Biol Chem. 2000;275:18447–53. doi:10.1074/jbc.M910345199.PubMedCrossRef

69.

Zhang Z, Kumar R, Santen RJ, Song RX. The role of adapter protein Shc in estrogen non-genomic action. Steroids 2004;69:523–9. doi:10.1016/j.steroids.2004.05.012.PubMedCrossRef

70.

Klijn JG, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol. 2001;19:343–53.PubMed

71.

Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131–9. doi:10.1016/S0140-6736(02)09088-8.PubMedCrossRef

72.

Mackey J, et al. Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer. Breast Cancer Res Treat 2006;100:S5. abstract 3.

73.

Lisztwan J, Pornon A, Chen B, Chen S, Evans DB. The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer. Breast Cancer Res. 2008;10:R56. doi:10.1186/bcr2113.PubMedCrossRef

74.

Osborne R. Commercial interest waxes for IGF-1 blockers. Nat Biotechnol. 2008;26:719–20. doi:10.1038/nbt0708-719.PubMedCrossRef

75.

Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE, et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res. 2005;11:2063–73. doi:10.1158/1078–0432.CCR-04-1070.PubMedCrossRef

76.

Creighton CJ, Casa A, Lazard Z, Huang S, Tsimelzon A, Hilsenbeck SG, et al. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol. 2008;26:4078–85.PubMedCrossRef

77.

Yee D. Can the insulin-like growth factors regulate breast cancer growth? Breast Cancer Res Treat. 1992;22:3–5. doi:10.1007/BF01833328.PubMedCrossRef

Title: Crosstalk Between IGF1R and Estrogen Receptor Signaling in Breast Cancer
Authors: Dedra H. Fagan
Douglas Yee
Publication date: 01-12-2008
Publisher: Springer US
Published in: Journal of Mammary Gland Biology and Neoplasia / Issue 4/2008
Print ISSN: 1083-3021
Electronic ISSN: 1573-7039
DOI: https://doi.org/10.1007/s10911-008-9098-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2008

Role of Insulin-Like Growth Factor Binding Proteins in Mammary Gland Development

Insulin Receptor Substrates (IRSs) and Breast Tumorigenesis

IGF-1 Receptor Inhibitors in Clinical Trials—Early Lessons

IGF Binding Proteins (IGFBPs) and Regulation of Breast Cancer Biology

IGF-I, GH, and Sex Steroid Effects in Normal Mammary Gland Development

The Impact of Transgenic IGF-IR Overexpression on Mammary Development and Tumorigenesis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer